PRIMED HEALTH LIMITED

Executive Summary

Primed Health Limited is a nascent pharmaceutical manufacturing startup exhibiting stable but very modest financial health, with positive cash flow capacity but limited assets and minor losses typical of early-stage ventures. The company's financial condition is cautiously stable, warranting close management of costs and proactive revenue development to improve profitability and resilience. Strategic funding and rigorous financial oversight will be key to moving from fragile stability to robust growth.

PRIMED HEALTH LIMITED - Analysis Report

Company Number: 14228932

Analysis Date: 2025-07-29 20:41 UTC

Financial Health Assessment of Primed Health Limited

---

1. Financial Health Score: C

Explanation:
Primed Health Limited shows a very modest but stable financial position with a small positive net asset base and minimal liabilities. The company is in an early stage (incorporated in 2022), with limited operational scale and financial activity, reflected by consistently low current assets and liabilities. The slight decline in net assets and presence of a small profit and loss deficit indicate early "symptoms" of financial strain, but nothing critical at this stage. The grade C reflects a cautiously stable but fragile condition, typical for a micro-sized startup in a capital-intensive industry like pharmaceutical manufacturing.

---

2. Key Vital Signs

Metric	2024 Value	Interpretation
Current Assets	£1,000	Very low; primarily cash, indicating limited operational scale.
Cash	£1,000	Entire current asset base is cash; positive for liquidity.
Current Liabilities	£180	Low short-term debt; manageable at this scale.
Net Current Assets	£820	Positive working capital, indicating ability to cover short-term debts.
Net Assets (Equity)	£820	Small but positive net worth; equity buffer slightly reduced from prior year.
Shareholders' Funds	£1,000	Capital invested by owners remains intact but profit & loss shows a deficit.
Profit and Loss Account	-£180	Indicates accumulated losses; early "symptom" of operational costs exceeding income.
Average Employees	1	Minimal human resource; typical for early-stage micro entity.

---

3. Diagnosis

Primed Health Limited presents as a micro-sized, start-up entity in the manufacture of basic pharmaceutical products, a sector with high barriers to entry and significant research and development costs. The company's financials show:

• Healthy liquidity ("cash in hand") relative to liabilities, signifying the company can meet immediate obligations without stress.
• Low operational scale and minimal asset base, indicating limited business activity so far.
• Accumulated deficit in the profit and loss reserve, reflecting that the company has incurred some operating losses, common in early years for pharmaceutical ventures.
• Stable capital structure with shareholder funds intact, but a modest erosion in net assets due to losses.

The "symptoms" of distress are mild and typical for a new venture still in its formative phase, likely investing in product development or market entry rather than generating meaningful revenues yet. The company's financial health is stable but remains vulnerable due to its small scale and lack of diversified assets or revenue streams.

---

4. Recommendations

To improve financial wellness and strengthen the company's "vital signs," consider the following actions:

• Enhance revenue generation: Accelerate commercialization efforts or partnerships to bring products to market and improve cash inflows.
• Control operating costs: Closely monitor and manage expenses to limit further erosion of equity and improve profitability.
• Seek additional funding: Explore options for equity investment, grants, or loans tailored to pharmaceutical startups to build a stronger capital base.
• Build working capital reserves: Aim to increase cash reserves beyond current minimal levels to buffer operational risks.
• Regular financial monitoring: Establish monthly cash flow forecasting to identify emerging liquidity issues early and adjust operational plans.
• Document strategic milestones: Use financial reports to communicate progress to investors and stakeholders, reinforcing confidence in the company's growth trajectory.

---